Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ELDNBearishResearch Analysisnews

High materiality8/10

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Nov 7, 2025, 1:56 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The significant drop in stock price reflects disappointment in trial results, reminiscent of historical drops after clinical trial failures. For instance, companies like Regenron faced similar declines when pivotal trials underperformed.

AI summary

What happened, with direct paths to the underlying reporting

Eledon stock down 59% after Phase 2 trial results. Tegoprubart showed higher eGFR but missed primary efficacy endpoints. The drug is moving to Phase 3 despite trial failures. Eledon has $93.4 million cash runway into late 2026. Phase 2 trial had significant patient volume, indicating strong interest.

Eledon stock down 59% after Phase 2 trial results.
Tegoprubart showed higher eGFR but missed primary efficacy endpoints.
The drug is moving to Phase 3 despite trial failures.
Eledon has $93.4 million cash runway into late 2026.
Phase 2 trial had significant patient volume, indicating strong interest.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.